Delcath Systems reports Q4/FY2023 results; first HEPZATO KIT use, site guidance raised to 20

DELCATH SYSTEMS, INC.

First commercial HEPZATO KIT treatment for metastatic uveal melanoma performed at Moffitt Cancer Center.
Increased 2024 active treatment site guidance from 15 to 20 sites; three sites activated, four more imminent.
Product-specific J-code (J9248) and transitional pass-through payment effective April 1, 2024, from CMS.
Appointed Dr. Martha S. Rook as COO; raised $7.0M in private placement from insiders and existing investors.
Cash $32.5M at Dec 31, 2023; FY2023 revenue $2.1M (down from $2.7M); SG&A increased to $22.1M for commercial prep.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.

Period: fourth quarter and full year ended December 31, 2023
Revenue: approximately $0.5 million and $2.1 million, respectively
Guidance: raised
Result: reported results

Exact text from the filing

to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-012996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.